ISPOR - Cost-Effectiveness of a Fixed-Dose Combination Therapy of Lesinurad and Allopurinol for Second-Line Gout Therapy- A US Payer Perspective

Full Text

Cost-Effectiveness of a Fixed-Dose Combination Therapy of Lesinurad and Allopurinol for Second-Line Gout Therapy- A US Payer Perspective

Abstract

Authors

P Khanna D Taylor R Morlock A Fu

Back to Volume 21, Supplemental S1

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now